Kezar Life Sciences, Inc.

Healthcare · Biotechnology · United States

Last price 7.29 USD (At close: May 8, 2026) · Market cap 53.86M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South...